Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia - A physician survey., PMID:40480942
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650
Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials., PMID:40478366
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis., PMID:40467521
Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE-/- mice., PMID:40462197
Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry., PMID:40450473
Association between novel agents targeting proprotein convertase subtilisin/kexin type 9 and cancer incidence., PMID:40447742
Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy., PMID:40439109
Relationship Between Timing of PCSK9 Inhibitor Monoclonal Antibody Initiation and Clinical Outcomes in Patients with Prior Cardiovascular Events., PMID:40417171
Design of the "EAST" strategy in patients with symptomatic intracranial atherosclerotic stenosis., PMID:40417113
An evaluation of recaticimab for the treatment of hypercholesterolemia., PMID:40380894
Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins: A novel gene therapy approach., PMID:40360039
Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis., PMID:40358978
RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study., PMID:40347490
Comment on "effect of PCSK9 antibodies on coronary plaque regression and stabilization derived from intravascular imaging in patients with coronary artery disease: A meta-analysis"., PMID:40339754
Proprotein convertase subtilisin/kexin type 9 contributes to cisplatin-induced acute kidney injury by interacting with cyclase-associated protein 1 to promote megalin lysosomal degradation., PMID:40339661
Prescriber Uptake and Use of Novel Lipid-Lowering Therapies., PMID:40314342
Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects., PMID:40305153
Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study., PMID:40270128
Recent Advances in the Management of Dyslipidemia: A Systematic Review., PMID:40264627
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial., PMID:40255182
A Phase I Study to Evaluate the Relative Bioavailability, Pharmacodynamics, and Safety of a Single Subcutaneous Injection of Recaticimab at Three Different Sites in Healthy Chinese Subjects., PMID:40252193
Inadequate Response to PCSK9 Inhibitors., PMID:40250948
Effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in managing hypercholesterolemia post-statin-associated immune-mediated necrotizing myopathy: report of five cases and literature review., PMID:40249406
High-Intensity Statins Promote PCSK9 Secretion and aortic valve calcification in patients with severe aortic stenosis: In vitro and clinical evidence., PMID:40239750
Multilevel Factors Predict Medication Adherence and Efficacy within 12 Months in Patients Receiving PCSK9 Monoclonal Antibodies: The Findings from a Real-World Analysis in China., PMID:40189248
Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography., PMID:40178463
Tafolecimab, a Third Monoclonal Antibody for PCSK9 as the Novel Lipid-Lowering Drug Around the World: A Narrative Review., PMID:40167967
Target-Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data., PMID:40136083
"Are new lipid lowering agents a good option for achieving lipid goals in people living with HIV? A case report"., PMID:40123063
Immunotherapy and vaccine-based approaches for atherosclerosis prevention: a systematic review study., PMID:40114074
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies., PMID:40110803
Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan., PMID:40089775
PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling., PMID:40076547
Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial., PMID:40045751
Challenges in Achieving LDL Cholesterol Targets and Novel Approaches to Lipid Lowering., PMID:40043177
Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk., PMID:40020784
Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS., PMID:40020597
Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial., PMID:40001082
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial., PMID:39999660
Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria., PMID:39964484
Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice., PMID:39963241
Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization., PMID:39952371
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?, PMID:39947256
In Situ Self-Assembly of Artificial Topological Nanostructures Enhances In Vivo Efficacy of PCSK9 Inhibitory Peptides., PMID:39945488
PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose., PMID:39940773
Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes., PMID:39930254
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial., PMID:39913634
Ebronucimab: First Approval., PMID:39913020
Long-Term Lipid Lowering With Evolocumab in Older Individuals., PMID:39909681
For research use only. Not for human or drug use.
